Bendamustin

DRUG5 trials

Sponsors

University Hospital Tuebingen, ECOG-ACRIN Cancer Research Group, Meir Medical Center, Ruijin Hospital, The Lymphoma Academic Research Organisation

Conditions

Follicular LymphomaLymphomaLymphoma, Mantle-CellSarcoma, Soft Tissue

Phase 2

Bendamustin Hydrochloride in Patients With Soft Tissue Sarcoma (STS)

CompletedNCT00204620

University Hospital TuebingenSarcoma, Soft Tissue

Start: 2002-03-31End: 2006-12-31Target: 28Updated: 2007-04-20

Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

CompletedNCT01216683

ECOG-ACRIN Cancer Research GroupLymphoma

Start: 2011-02-09End: 2019-12-02Updated: 2023-06-29

Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status

Meir Medical CenterFollicular Lymphoma

Start: 2020-01-29End: 2025-08-01Target: 40Updated: 2021-06-22

A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma

RecruitingNCT06136351

Ruijin HospitalLymphoma, Mantle-Cell

Start: 2023-11-15End: 2027-11-01Target: 23Updated: 2023-11-29

Phase 3

Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

RecruitingNCT06284122

The Lymphoma Academic Research OrganisationFollicular Lymphoma

Start: 2024-06-07End: 2034-04-30Target: 790Updated: 2024-10-15

Related Papers

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies

Blood2024-10-2449 citations

A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408

Clinical Cancer Research2020-06-1222 citations

Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial.

2012-10-2217 citations